Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Mainstay Medical Holdings plc

Mainstay Medical Announces Positive Coverage Decision for ReActiv8® from Highmark Inc.

July 28, 2026

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota

February 04, 2026

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8

December 11, 2025

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

April 28, 2025

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®

January 15, 2025

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM

July 09, 2024

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up

March 19, 2024

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients

March 12, 2024

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces US$125 Million Equity Financing Transaction

February 26, 2024

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM

February 12, 2024

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States

August 29, 2023

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom

July 20, 2023

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™

September 28, 2022

From Mainstay Medical Holdings plc

Via Business Wire

United Kingdom National Institute for Health and Care Excellence (NICE) Publishes Interventional Procedure Guidance (IPG) for ReActiv8® Restorative Neurostimulation™

September 23, 2022

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Publication of Two-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™

January 06, 2022

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors

December 14, 2021

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Participation at the American Association of Neurological Surgeons (AANS) Annual Meeting

August 23, 2021

From Mainstay Medical Holdings plc

Via Business Wire

Mainstay Medical Announces Limited Commercial Launch of ReActiv8® in the U.S.

June 29, 2021

From Mainstay Medical Holdings plc

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.